What are the latest figures on the encephalomyelitis market’s size and projected CAGR?
The encephalomyelitis market size has grown strongly in recent years. It will grow from $21.16 billion in 2024 to $22.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increase in prevalence of autoimmune and infectious diseases, growth in awareness of neurological disorders, rise in investment in research and development, improved healthcare infrastructure, and expansion of immunotherapy applications.
The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $29.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing prevalence of autoimmune disorders, rising healthcare expenditure, expanding clinical research, enhanced awareness and education about encephalomyelitis, and rising government and private funding for rare disease research. Major trends in the forecast period include development of advanced immunomodulatory therapies, advancements in precision biologics, novel biomarkers for early diagnosis, advancements in personalized treatment, development of next-generation antivirals, integration of AI in clinical research, and innovative gene therapy approaches.
Get Your Free Sample of The Global Encephalomyelitis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21182&type=smp
Which Market drivers have played a significant role in driving the encephalomyelitis market?
The growing prevalence of autoimmune diseases is expected to propel the growth of the encephalomyelitis market going forward. Autoimmune diseases refer to conditions in which the body’s immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is attributed to factors such as genetic predisposition, environmental triggers, infections, and changes in lifestyle, including diet and exposure to chemicals. Encephalomyelitis treatment supports autoimmune disease patients by reducing inflammation, managing immune system dysfunction, alleviating neurological symptoms, and preventing disease progression, ultimately improving their overall quality of life and functional well-being. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based organization, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the encephalomyelitis market.
What are the key segments within the encephalomyelitis market?
The encephalomyelitis market covered in this report is segmented –
1) By Type: Equine Encephalomyelitis, Associated Encephalomyelitis, Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG), Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis, Other Types
2) By Treatment: Surgery , Plasmapheresis, Drug Treatment, Other Treatments
3) By End-users: Clinics , Hospitals, Other End-Users
Subsegments:
1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis
2) By Associated Encephalomyelitis: Acute Disseminated Encephalomyelitis, Paraneoplastic Encephalomyelitis, Infectious Encephalomyelitis
3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody: Monophasic Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis, Relapsing Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
4) By Encephalomyelitis: Viral Encephalomyelitis, Bacterial Encephalomyelitis, Autoimmune Encephalomyelitis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/encephalomyelitis-global-market-report
Which key players are shaping the encephalomyelitis market?
Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.
Which transformative trends will shape the encephalomyelitis market landscape?
Major companies operating in the encephalomyelitis market are focusing on developing advanced monoclonal antibody, to enhance treatment efficacy and develop targeted therapies for managing encephalomyelitis. Monoclonal antibody is an artificially created protein that attaches to specific antigens to aid the immune response against diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd, a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng has received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its anticipated use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation recognizes Enspryng’s potential as an innovative treatment, expediting its development and regulatory review to address the unmet medical needs of patients with these neurological conditions.
How do regional factors impact the encephalomyelitis market, and which region is the largest contributor?
North America was the largest region in the encephalomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the encephalomyelitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Encephalomyelitis Market Report 2025 Offer?
The encephalomyelitis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Encephalomyelitis refers to the inflammation affecting both the brain and spinal cord, resulting from infections, immune system dysfunction, or other medical conditions. This condition causes neurological issues, including muscle weakness, paralysis, and cognitive disturbances.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21182
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
